MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.waojou.2026.101449

Медицинская библиотека · The World Allergy Organization journal · 2026

Prevalence and cost implications of broadening asthma biologic eligibility criteria.

Yang Freda, Geisler Benjamin P, d'Ancona Grainne, Lee Bohee, Jackson David J, Bloom Chloe I

СтатьяПеревод в очереди

Аннотация

RATIONALE: Eligibility for biologic therapy in severe asthma varies internationally because government-funded schemes apply stricter criteria than pivotal trials. While relaxing eligibility thresholds may expand access, the effects on prevalence and healthcare costs remain uncertain.

OBJECTIVE

To quantify how alternative biologic eligibility criteria affect prevalence, clinical characteristics, and budget impact in adults with asthma.

METHODS

We studied adults with active asthma (2004-2021) using nationally representative primary care and hospital records. Biologic eligibility was assessed yearly using asthma severity (inhaled corticosteroid dose, additional controllers, rescue therapy) and exacerbations (oral corticosteroid prescriptions, emergency visits and hospitalisations). We assessed prevalence using United Kingdom (UK) criteria (severe asthma, ≥3 exacerbations), Global criteria (severe asthma, ≥1 or ≥2 exacerbations) and RCT criteria (moderate asthma, ≥1 or ≥2 exacerbations). Anti-IL-5/5Rα eligibility was evaluated using blood eosinophil counts. Budget impact was modelled over 5 years.

RESULTS

Among 1,306,307 asthma patients, 7.2% had severe asthma. Under UK criteria, 19,093 patients were biologic-eligible (20.4% of severe asthma; 1.5% of all asthma). Global criteria increased eligibility to 2.4% (≥2 exacerbations) to 4.3% (≥1 exacerbation), while RCT criteria expanded eligibility to 4.7% (≥2 exacerbations) and 9% (≥1 exacerbation). Among patients with eosinophil data, 38-45% met anti-IL-5/5Rα criteria. UK-eligible patients had higher prevalence of lower respiratory tract infections, pneumonia, and bronchiectasis. Five-year costs were £261 M under UK criteria, £436-767 M under Global criteria, and £878M-1.6B under RCT criteria.

CONCLUSION

Only one-fifth of patients with severe asthma met UK biologic eligibility. Global criteria tripled eligibility and RCT criteria increased it six-fold, with substantial budget implications.

Для цитирования: Yang Freda, Geisler Benjamin P, d'Ancona Grainne, Lee Bohee, Jackson David J, Bloom Chloe I. Prevalence and cost implications of broadening asthma biologic eligibility criteria.. The World Allergy Organization journal. 2026. DOI: 10.1016/j.waojou.2026.101449.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.